A COMBINATION THERAPY FOR REFRACTORY INVASIVE CANDIDIASIS IN A LIVER TRANSPLANT RECIPIENT
A well-established clinical procedure for treating terminal liver diseases is liver transplantation (LT). Invasive fungal infections (IFI) can be seen in about 5-7 percent of liver transplant recipients, regardless of the use of antifungal prophylaxis.?
As a result, IFI continues to present a challenge for treating physicians, and the use of antifungal combination therapy is frequently thought to increase response rates. However, there is a dearth of clinical evidence to support the use of antifungal combination therapy in place of a single agent for the treatment of patients with invasive candidiasis?
?This is the first report describing a patient who had a liver transplant and had refractory invasive candidiasis who was successfully treated with isavuconazole (ISA) and liposomal amphotericin B (AMB).
The case report explains that in a liver transplant recipient with invasive candidiasis, antifungal co-treatment with isavuconazole (ISA) and liposomal amphotericin B (AMB) offers efficacy and a favourable side effect profile. Thus, antimycotic combination therapy may be a promising treatment option for immunocompromised patients with persistent candidemia.?